Synopsis
Identify hypothalamic-pituitary-adrenal suppression from every glucocorticoid route, separate withdrawal from disease relapse, and taper safely while maintaining stress cover and crisis readiness.
- Exogenous glucocorticoids suppress CRH and ACTH, causing adrenal atrophy; recovery varies widely and cannot be predicted from dose duration alone.
- Count oral, injected, inhaled, intranasal, topical and rectal exposure together, including repeated joint injections and CYP3A4 interactions that increase systemic steroid concentrations.
- For adults treated longer than four weeks, reduce toward a physiological equivalent only after the underlying inflammatory or malignant indication no longer requires a higher therapeutic dose.
- NICE suggests a slower final withdrawal after courses beyond twelve weeks and allows testing in adults when symptoms persist despite an appropriate slow taper.
- Glucocorticoid withdrawal syndrome can cause fatigue, anorexia, low mood, myalgia and arthralgia despite an adequate cortisol dose; distinguish it from adrenal insufficiency and recurrence of the treated disease.
- Do not measure morning cortisol while oral glucocorticoid exposure is still at or above physiological replacement, because suppression is expected and the result will not answer whether tapering is safe.
- When NICE-directed morning cortisol testing is indicated, withhold hydrocortisone, prednisolone or dexamethasone for their specified intervals and use local assay thresholds.
- Any patient at meaningful suppression risk needs sick-day and procedure advice, an NHS Steroid Emergency Card where indicated, and immediate parenteral hydrocortisone if crisis is suspected.
Key red flags
Hypotension, collapse, confusion, hypoglycaemia or severe vomiting after steroid reduction warrants immediate treatment for adrenal crisis without awaiting cortisol results.
Inability to retain oral steroid during gastroenteritis requires emergency injection and hospital assessment because repeating swallowed doses cannot guarantee absorption.
Severe breathlessness, neurological deficit, inflammatory organ dysfunction or other objective relapse features may require restoration of disease-treatment dosing alongside endocrine protection.
A patient taking ritonavir or cobicistat with a potent inhaled, injected or topical glucocorticoid needs urgent interaction review; abrupt removal can unmask profound suppression.
Major surgery or invasive procedure without a documented stress-dose plan exposes a suppressed patient to avoidable perioperative shock.
Investigation priorities
Estimate suppression risk across prescription, procedure and non-prescription routes.
Management branches
A systemic or locally delivered glucocorticoid course is being reduced or stopped.
- List all preparations, duration, cumulative pattern, depot injections and interacting medicines, and identify the prescriber responsible for the original disease.
- Decide whether therapeutic steroid is still required; do not taper inflammatory control merely to perform an endocrine test.
- Issue current emergency-card and stress-dose information when exposure meets the relevant risk pathway, involving the patient and carers.
- Reduce toward physiological equivalence using disease response, then choose the NICE final-taper route based on duration and symptoms.